aspirin has been researched along with Esophageal Neoplasms in 102 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 9.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| " Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users." | 9.05 | Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis. ( Cao, LL; Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JX; Lin, M; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2020) |
| "To review the advances of studies on clinical results of aspirin's chemopreventive effect against esophageal squamous cell carcinoma (ESCC) and evidences for mechanisms of the antitumoural effects of aspirin in experimental research." | 8.90 | Aspirin and esophageal squamous cell carcinoma: bedside to bench. ( Cheng, R; Li, P; Zhang, S, 2014) |
| "The role of aspirin use in chemoprevention of esophageal adenocarcinoma (EAC) is still unclear." | 8.90 | The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis. ( Pengcheng, X; Sidong, C; Weidong, L; Xiaohua, Y; Zhenjiang, Y, 2014) |
| "To investigate the expression of ATPase family AAA domain-containing protein 2 (ATAD2) and kinesin family member 4A (KIF4A) in esophageal squamous cell carcinoma (ESCC) tissues and their association with clinicopathological features and to explore the role of ATAD2 in regulating KIF4A expression and biological functions in ESCC cells and the effect of aspirin on their expression." | 8.12 | Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A. ( Liu, C; Liu, H; Ren, Z; Wang, X; Zhang, M; Zhao, J; Zheng, Z, 2022) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)." | 7.81 | NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015) |
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 7.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| "Our data demonstrated that low dose aspirin reduced the incidence of duodenoesophageal reflux induced histological changes in the esophagus by preventing activation of proliferative & anti-apoptotic MAP kinases such as p38 & ER as well as protease activity." | 7.78 | Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways. ( Amirtharaj, GJ; Kettimuthu, K; Korula, A; Mathew, G; Nair, A; Nair, S; Ramachandran, A; Samuel, P; Selvan, B, 2012) |
| "Deoxycholic acid induced MUC2 overexpression in human esophageal adenocarcinoma cells by activation of Nuclear factor-kappaB transcription through a process involving PKC-dependent but not PKA, independent of activation of MAP kinase." | 7.74 | Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells. ( Geng, J; Gong, J; Song, Y; Wu, J, 2008) |
| " The aspirin analogues fumaryldiaspirin (PN517) and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more toxic against the OC cell lines than aspirin." | 5.51 | The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer. ( Bashir, AIJ; Devitt, A; Kilari, RS; Nicholl, ID; Perry, CJ; Safrany, ST, 2019) |
| "Preclinical, epidemiological, and randomised data indicate that aspirin might prevent tumour development and metastasis, leading to reduced cancer mortality, particularly for gastro-oesophageal and colorectal cancer." | 5.30 | Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. ( Adams, R; Berkman, L; Bridgewater, J; Cafferty, F; Cameron, D; Crossley, A; Din, F; Falk, S; Gilbert, D; Graham, J; Gupta, K; Henson, V; Hubner, R; Iveson, T; Jankowski, J; Joharatnam-Hogan, N; Khabra, K; Kunene, V; Kynaston, H; Langley, R; Patel, K; Pramesh, CS; Ring, A; Rowley, S; Sothi, S; Swinson, D; Thomas, A; Underwood, T; Warner, N; Wilson, R, 2019) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 5.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| " Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users." | 5.05 | Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis. ( Cao, LL; Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JX; Lin, M; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2020) |
| "To review the advances of studies on clinical results of aspirin's chemopreventive effect against esophageal squamous cell carcinoma (ESCC) and evidences for mechanisms of the antitumoural effects of aspirin in experimental research." | 4.90 | Aspirin and esophageal squamous cell carcinoma: bedside to bench. ( Cheng, R; Li, P; Zhang, S, 2014) |
| "The role of aspirin use in chemoprevention of esophageal adenocarcinoma (EAC) is still unclear." | 4.90 | The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis. ( Pengcheng, X; Sidong, C; Weidong, L; Xiaohua, Y; Zhenjiang, Y, 2014) |
| "Aspirin and other NSAIDs are showing promise in the chemoprevention of colorectal cancer." | 4.80 | Non-steroidal anti-inflammatory drugs and chemoprevention of cancer. ( Morgan, G; Vainio, H, 2000) |
| "To investigate the expression of ATPase family AAA domain-containing protein 2 (ATAD2) and kinesin family member 4A (KIF4A) in esophageal squamous cell carcinoma (ESCC) tissues and their association with clinicopathological features and to explore the role of ATAD2 in regulating KIF4A expression and biological functions in ESCC cells and the effect of aspirin on their expression." | 4.12 | Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A. ( Liu, C; Liu, H; Ren, Z; Wang, X; Zhang, M; Zhao, J; Zheng, Z, 2022) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)." | 3.81 | NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015) |
| "An estimated 335 colorectal cancers, 22 oesophageal adenocarcinomas and 29 oesophageal squamous cell carcinomas (SCC) were potentially prevented due to daily aspirin use." | 3.81 | Cancers prevented in Australia in 2010 through the consumption of aspirin. ( Bain, CJ; Green, AC; Jordan, SJ; Kendall, BJ; Nagle, CM; Neale, RE; Whiteman, DC; Wilson, LF, 2015) |
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 3.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| "Data suggest that aspirin, statins, or a combination of the two drugs may lower the progression of Barrett's esophagus to esophageal adenocarcinoma." | 3.80 | Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. ( Choi, SE; Hur, C; Kong, CY; Perzan, KE; Tramontano, AC, 2014) |
| "Our data demonstrated that low dose aspirin reduced the incidence of duodenoesophageal reflux induced histological changes in the esophagus by preventing activation of proliferative & anti-apoptotic MAP kinases such as p38 & ER as well as protease activity." | 3.78 | Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways. ( Amirtharaj, GJ; Kettimuthu, K; Korula, A; Mathew, G; Nair, A; Nair, S; Ramachandran, A; Samuel, P; Selvan, B, 2012) |
| "Deoxycholic acid induced MUC2 overexpression in human esophageal adenocarcinoma cells by activation of Nuclear factor-kappaB transcription through a process involving PKC-dependent but not PKA, independent of activation of MAP kinase." | 3.74 | Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells. ( Geng, J; Gong, J; Song, Y; Wu, J, 2008) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts." | 2.82 | ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ( Berkman, L; Cafferty, FH; Cameron, D; Coyle, C; Gilbert, D; Gupta, S; Kynaston, H; Langley, RE; MacKenzie, M; Pramesh, CS; Ring, A; Rowley, S; Wilson, RH, 2016) |
| "Candidates for chemoprevention in Barrett's esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin." | 2.72 | Current Status of Chemoprevention in Barrett's Esophagus. ( El-Serag, HB; Moayyedi, P, 2021) |
| "Abdominal obesity, independently of gastroesophageal reflux disease symptoms, is associated with increased risk of Barrett's esophagus and this association is likely mediated by high levels of leptin and insulin." | 2.53 | Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. ( Thrift, AP, 2016) |
| "Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas." | 2.47 | Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011) |
| "Oesophageal cancer is on the rise and often present in an advanced state." | 2.45 | Chemoprevention of oesophageal cancer and the AspECT trial. ( Chilton, AP; Das, D; Jankowski, JA, 2009) |
| "In patients with Barrett's esophagus, medical treatment is necessary for the control of reflux symptom, healing of accompanying erosive esophagitis, and prevention of carcinogenesis." | 2.43 | [Medical treatment of Barrett's esophagus]. ( Kinoshita, Y; Yuki, T, 2005) |
| "For the prevention of oesophageal cancer, antitumour-B and retinamide have provided hopeful results, although it is not clear that these findings can be extrapolated from the study populations in Asia to western countries." | 2.43 | Chemoprevention in gastrointestinal cancers: current status. ( Baron, JA; Grau, MV; Rees, JR, 2006) |
| " There are now more than 15 epidemiological (case-control and cohort) studies indicating that long-term use of aspirin is associated with a reduced risk of colorectal cancer." | 2.41 | Aspirin and cancer risk: an update to 2001. ( Bosetti, C; Gallus, S; La Vecchia, C, 2002) |
| "The relative risk of colorectal cancer is about 0." | 2.41 | Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. ( Sjödahl, R, 2001) |
| "Oesophageal adenocarcinoma is characterised by a strong male predominance." | 1.72 | Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH, 2022) |
| "The association of oesophageal cancer with drug use and clinical factors was evaluated." | 1.72 | Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study. ( Arai, J; Arai, M; Hasatani, K; Hayakawa, Y; Honda, T; Ikeya, T; Kawahara, T; Kawai, T; Kiyotoki, S; Koike, K; Niikura, R; Nishida, T; Sumiyoshi, T; Suzuki, N; Tsuji, Y; Yamada, A; Yoshida, N, 2022) |
| "Barrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia." | 1.72 | Barrett Esophagus: Rapid Evidence Review. ( Bryce, C; Bucaj, M; Gazda, R, 2022) |
| "We identified 727 incident cases of gastric cancer and 1394 incident cases of oesophageal cancer." | 1.56 | Low-dose aspirin and risk of gastric and oesophageal cancer: A population-based study in the United Kingdom using The Health Improvement Network. ( Cea Soriano, L; García Rodríguez, LA; Soriano-Gabarró, M; Vora, P, 2020) |
| "There were 291 esophageal cancer patients who received neoadjuvant/definitive chemoradiation therapy." | 1.56 | Concurrent β-blocker Use is Associated With Improved Outcome in Esophageal Cancer Patients Who Undergo Chemoradiation: A Retrospective Matched-pair Analysis. ( Farrugia, MK; Flaherty, L; Ma, SJ; Mattson, DM; Repasky, EA; Singh, AK, 2020) |
| " The aspirin analogues fumaryldiaspirin (PN517) and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more toxic against the OC cell lines than aspirin." | 1.51 | The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer. ( Bashir, AIJ; Devitt, A; Kilari, RS; Nicholl, ID; Perry, CJ; Safrany, ST, 2019) |
| "Aspirin use has been shown to lower incidence and mortality in cancer patients." | 1.43 | The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients. ( Bastiaannet, E; de Steur, WO; Frouws, M; Hartgrink, HH; Lemmens, V; Liefers, GJ; Reimers, M; van de Velde, CJ; van Herk-Sukel, MP; van Staalduinen, J, 2016) |
| " It is unclear whether their long-term use affects cancer risk." | 1.42 | Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer. ( Macfarlane, TV; Murchie, P; Watson, MC, 2015) |
| "The incidence of esophageal and gastric cancers was high at 5." | 1.36 | Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy: preliminary study. ( Kawai, T; Watanabe, M; Yamashina, A, 2010) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "Aspirin can inhibit the cell growth and suppress the protein level of cyclin D(1) after CSE affected EC109 cell line." | 1.35 | Influence of aspirin and cigarette smoke extract on the expression of cyclin D1 and effects of cell cycle in esophageal squamous cell carcinoma cell line. ( Hu, H; Zhang, S; Zhu, S, 2009) |
| "Pretreatment with aspirin and nimesulide inhibited EC9706 and EC109 cell growth in a time and dose-dependent manner, accompanied with a decrease of prostaglandin E2 production." | 1.35 | Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells. ( Cho, CH; Li, P; Liu, X; Wu, YD; Xu, CM; Yu, ZL; Zhang, ST, 2009) |
| "Aspirin could inhibit the proliferation of cell lines EC109 and EC9706, pretreated with EE for 5 hours, in a dose-dependent manner." | 1.34 | Aspirin inhibits the proliferation of tobacco-related esophageal squamous carcinomas cell lines through cyclooxygenase 2 pathway. ( Ding, XC; Li, P; Liu, HB; Yu, ZL; Zhang, ST; Zhou, QZ, 2007) |
| "The oesophageal squamous cell carcinoma cell line TE-13 was cultured with aspirin at different concentrations or for different times." | 1.33 | Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2. ( Drew, PA; Jamieson, GG; Liu, JF; Shan, BE; Wang, QZ; Zhang, SW; Zhu, GJ; Zhu, TN, 2005) |
| "Results suggest that esophageal cancer risk is significantly lower for regular aspirin users compared to nonusers [adjusted odds ratio (aOR) 0." | 1.33 | Regular aspirin use and esophageal cancer risk. ( Baker, JA; Javle, MM; Jayaprakash, V; McCann, SE; Menezes, RJ; Moysich, KB; Natarajan, N; Reid, ME, 2006) |
| "In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited." | 1.33 | Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. ( Anderson, LA; Comber, H; Ferguson, HR; Johnston, BT; McGuigan, J; Murphy, SJ; Murray, LJ; Reynolds, JV; Watson, RG, 2006) |
| "Complications of Zenker's diverticulum are rare and include ulcer, bleeding and malignancy." | 1.33 | Ulcer in the basis of Zenker's diverticulum mimicking esophageal malignancy. ( Ataseven, H; Basar, O; Ertugrul, I; Odemis, B; Turhan, N; Yüksel, O, 2006) |
| "Aspirin therapy was more effective and less costly than no therapy, resulting in 0." | 1.32 | Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. ( Gazelle, GS; Hur, C; Nishioka, NS, 2004) |
| "We have reported reduced risk of fatal colon cancer among persons who used aspirin in a large prospective study." | 1.29 | Aspirin use and risk of fatal cancer. ( Calle, EE; Flanders, WD; Heath, CW; Namboodiri, MM; Thun, MJ, 1993) |
| "Aspirin use was associated with a 90% decreased risk of developing esophageal carcinoma." | 1.29 | Aspirin and reduced risk of esophageal carcinoma. ( Funkhouser, EM; Sharp, GB, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (9.80) | 18.2507 |
| 2000's | 36 (35.29) | 29.6817 |
| 2010's | 41 (40.20) | 24.3611 |
| 2020's | 15 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, SH | 1 |
| Santoni, G | 1 |
| Lagergren, J | 2 |
| Arai, J | 1 |
| Niikura, R | 1 |
| Hayakawa, Y | 1 |
| Kawahara, T | 1 |
| Honda, T | 1 |
| Hasatani, K | 1 |
| Yoshida, N | 1 |
| Nishida, T | 1 |
| Sumiyoshi, T | 1 |
| Kiyotoki, S | 1 |
| Ikeya, T | 1 |
| Arai, M | 1 |
| Suzuki, N | 1 |
| Tsuji, Y | 1 |
| Yamada, A | 1 |
| Kawai, T | 2 |
| Koike, K | 1 |
| Jiang, J | 1 |
| Liu, J | 2 |
| Gao, P | 2 |
| Zhang, M | 1 |
| Ren, Z | 1 |
| Wang, X | 2 |
| Liu, C | 1 |
| Zheng, Z | 1 |
| Zhao, J | 1 |
| Liu, H | 1 |
| Bryce, C | 1 |
| Bucaj, M | 1 |
| Gazda, R | 1 |
| Holmberg, D | 1 |
| Gottlieb-Vedi, E | 1 |
| Hedberg, J | 1 |
| Lindblad, M | 1 |
| Mattsson, F | 1 |
| Li, H | 2 |
| Zhang, L | 4 |
| Yang, F | 1 |
| Zhao, R | 1 |
| Li, X | 1 |
| Joharatnam-Hogan, N | 1 |
| Cafferty, F | 1 |
| Hubner, R | 1 |
| Swinson, D | 1 |
| Sothi, S | 1 |
| Gupta, K | 1 |
| Falk, S | 1 |
| Patel, K | 1 |
| Warner, N | 1 |
| Kunene, V | 1 |
| Rowley, S | 2 |
| Khabra, K | 1 |
| Underwood, T | 2 |
| Jankowski, J | 5 |
| Bridgewater, J | 1 |
| Crossley, A | 1 |
| Henson, V | 1 |
| Berkman, L | 2 |
| Gilbert, D | 2 |
| Kynaston, H | 2 |
| Ring, A | 2 |
| Cameron, D | 2 |
| Din, F | 1 |
| Graham, J | 1 |
| Iveson, T | 1 |
| Adams, R | 1 |
| Thomas, A | 1 |
| Wilson, R | 1 |
| Pramesh, CS | 2 |
| Langley, R | 1 |
| Zhang, T | 1 |
| Wang, Q | 1 |
| Ma, WY | 1 |
| Wang, K | 2 |
| Chang, X | 1 |
| Johnson, ML | 1 |
| Bai, R | 1 |
| Bode, AM | 1 |
| Foster, NR | 1 |
| Falk, GW | 2 |
| Limburg, PJ | 1 |
| Iyer, PG | 1 |
| Dong, Z | 1 |
| Song, Y | 2 |
| Zhong, X | 1 |
| Zhou, C | 1 |
| Shi, J | 1 |
| Wu, Z | 1 |
| Guo, Z | 1 |
| Wang, Z | 1 |
| Wu, Y | 1 |
| Xu, F | 1 |
| Wang, T | 1 |
| Fu, X | 1 |
| Jin, T | 1 |
| Zhang, W | 1 |
| Ye, L | 1 |
| García Rodríguez, LA | 1 |
| Soriano-Gabarró, M | 1 |
| Vora, P | 1 |
| Cea Soriano, L | 1 |
| Lin, JL | 1 |
| Lin, JX | 1 |
| Zheng, CH | 1 |
| Li, P | 6 |
| Xie, JW | 1 |
| Wang, JB | 1 |
| Lu, J | 1 |
| Chen, QY | 1 |
| Cao, LL | 1 |
| Lin, M | 1 |
| Huang, CM | 1 |
| Farrugia, MK | 1 |
| Ma, SJ | 1 |
| Mattson, DM | 1 |
| Flaherty, L | 1 |
| Repasky, EA | 1 |
| Singh, AK | 1 |
| Moayyedi, P | 2 |
| El-Serag, HB | 2 |
| Zhao, Z | 1 |
| Yin, Z | 1 |
| Zhang, C | 1 |
| Zou, Z | 1 |
| Zheng, W | 1 |
| Fan, H | 1 |
| Deng, G | 1 |
| Lu, SH | 1 |
| Jiang, W | 1 |
| Yu, X | 1 |
| Spence, AD | 1 |
| Busby, J | 1 |
| Johnston, BT | 2 |
| Baron, JA | 2 |
| Hughes, CM | 1 |
| Coleman, HG | 1 |
| Cardwell, CR | 1 |
| Hvid-Jensen, F | 1 |
| Drewes, AM | 1 |
| Wang, D | 2 |
| Yue, DL | 1 |
| Chen, XF | 1 |
| Yin, XY | 1 |
| Wang, YP | 1 |
| Yang, L | 1 |
| Zhang, Y | 1 |
| Kilari, RS | 1 |
| Bashir, AIJ | 1 |
| Devitt, A | 1 |
| Perry, CJ | 1 |
| Safrany, ST | 1 |
| Nicholl, ID | 1 |
| Fitzgerald, RC | 1 |
| Corley, DA | 3 |
| Sivarasan, N | 1 |
| Smith, G | 1 |
| Choi, SE | 1 |
| Perzan, KE | 1 |
| Tramontano, AC | 1 |
| Kong, CY | 2 |
| Hur, C | 4 |
| Xiaohua, Y | 1 |
| Zhenjiang, Y | 1 |
| Weidong, L | 1 |
| Pengcheng, X | 1 |
| Sidong, C | 1 |
| Cowie, A | 1 |
| Noble, F | 1 |
| Cheng, R | 1 |
| Zhang, S | 2 |
| Esquivias, P | 2 |
| Cebrián, C | 2 |
| Morandeira, A | 1 |
| Santander, S | 3 |
| Ortego, J | 1 |
| García-González, MA | 2 |
| Lanas, A | 3 |
| Piazuelo, E | 3 |
| Masclee, GM | 1 |
| Coloma, PM | 1 |
| Spaander, MC | 1 |
| Kuipers, EJ | 1 |
| Sturkenboom, MC | 1 |
| Nelson, N | 1 |
| Wilson, LF | 1 |
| Green, AC | 3 |
| Kendall, BJ | 1 |
| Jordan, SJ | 1 |
| Nagle, CM | 1 |
| Bain, CJ | 2 |
| Neale, RE | 1 |
| Whiteman, DC | 4 |
| Macfarlane, TV | 1 |
| Murchie, P | 1 |
| Watson, MC | 1 |
| van Staalduinen, J | 1 |
| Frouws, M | 1 |
| Reimers, M | 1 |
| Bastiaannet, E | 1 |
| van Herk-Sukel, MP | 1 |
| Lemmens, V | 1 |
| de Steur, WO | 1 |
| Hartgrink, HH | 1 |
| van de Velde, CJ | 1 |
| Liefers, GJ | 1 |
| Thrift, AP | 2 |
| De Martino, A | 1 |
| Conde, B | 1 |
| Emperador, S | 1 |
| Carrera-Lasfuentes, P | 1 |
| Anderson, LA | 2 |
| Murray, LJ | 2 |
| Cook, MB | 1 |
| Shaheen, NJ | 2 |
| Rubenstein, JH | 1 |
| Vaughan, TL | 2 |
| Schneider, JL | 1 |
| Coyle, C | 1 |
| Cafferty, FH | 1 |
| MacKenzie, M | 1 |
| Gupta, S | 1 |
| Wilson, RH | 1 |
| Langley, RE | 1 |
| Zhang, ST | 6 |
| Yu, ZL | 4 |
| Wu, YD | 3 |
| Liu, X | 2 |
| Xu, CM | 3 |
| Cho, CH | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 2 |
| Gazelle, GS | 3 |
| Wu, J | 1 |
| Gong, J | 1 |
| Geng, J | 1 |
| Bazuro, GE | 1 |
| Torino, F | 1 |
| Gasparini, G | 1 |
| Capurso, L | 1 |
| Hu, H | 1 |
| Zhu, S | 1 |
| Das, D | 1 |
| Chilton, AP | 1 |
| Jankowski, JA | 3 |
| Liu, JF | 2 |
| Jamieson, GG | 2 |
| Wu, TC | 1 |
| Zhu, GJ | 2 |
| Drew, PA | 2 |
| Gatenby, PA | 1 |
| Ramus, JR | 1 |
| Caygill, CP | 1 |
| Winslet, MC | 1 |
| Watson, A | 1 |
| Tu, J | 2 |
| Pandeya, N | 2 |
| Webb, PM | 2 |
| Sadeghi, S | 2 |
| Szumiło, J | 1 |
| Burdan, F | 1 |
| Szumiło, M | 1 |
| Lewkowicz, D | 1 |
| Kedzierawska-Kurylcio, A | 1 |
| Hayeck, TJ | 1 |
| Yeh, JM | 1 |
| Richards, EM | 1 |
| Richards, EB | 1 |
| Spechler, SJ | 1 |
| Watanabe, M | 1 |
| Yamashina, A | 1 |
| Rizvi, S | 1 |
| Demars, CJ | 1 |
| Comba, A | 1 |
| Gainullin, VG | 1 |
| Rizvi, Z | 1 |
| Almada, LL | 1 |
| Lomberk, G | 1 |
| Fernández-Zapico, ME | 1 |
| Buttar, NS | 1 |
| Hooper, PA | 1 |
| Triadafilopoulos, G | 1 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Wang, F | 1 |
| Lv, ZS | 1 |
| Fu, YK | 1 |
| Scholl, S | 1 |
| Dellon, ES | 1 |
| Sun, L | 1 |
| Yu, S | 1 |
| Nicholson, A | 1 |
| Antonoff, MB | 1 |
| D'Cunha, J | 1 |
| Ma, GF | 1 |
| Gao, H | 1 |
| Chen, SY | 1 |
| Niu, YL | 1 |
| Selvan, B | 1 |
| Ramachandran, A | 1 |
| Korula, A | 1 |
| Amirtharaj, GJ | 1 |
| Kettimuthu, K | 1 |
| Nair, S | 1 |
| Nair, A | 1 |
| Samuel, P | 1 |
| Mathew, G | 1 |
| Thiagarajan, P | 1 |
| Beales, IL | 1 |
| Vardi, I | 1 |
| Dearman, L | 1 |
| Sanders, DS | 1 |
| Grabsch, H | 1 |
| Harrison, R | 1 |
| Bateman, A | 1 |
| Going, J | 1 |
| Goldin, R | 1 |
| Mapstone, N | 1 |
| Novelli, M | 1 |
| Walker, MM | 1 |
| Bosetti, C | 2 |
| Gallus, S | 1 |
| La Vecchia, C | 2 |
| Kerlikowske, K | 1 |
| Verma, R | 1 |
| Buffler, P | 1 |
| Talamini, R | 1 |
| Franceschi, S | 1 |
| Negri, E | 1 |
| Garavello, W | 1 |
| Scherübl, H | 1 |
| Sutter, AP | 1 |
| Zeitz, M | 1 |
| Garber, K | 1 |
| Xia, HH | 1 |
| Lam, SK | 1 |
| Lin, MC | 1 |
| Kung, HF | 1 |
| Wong, BC | 1 |
| Bardou, M | 1 |
| Barkun, AN | 1 |
| Ghosn, J | 1 |
| Hudson, M | 1 |
| Rahme, E | 1 |
| Scheiman, J | 1 |
| Kinoshita, Y | 1 |
| Yuki, T | 1 |
| Zhang, SW | 1 |
| Zhu, TN | 1 |
| Shan, BE | 1 |
| Wang, QZ | 1 |
| Jayaprakash, V | 1 |
| Menezes, RJ | 1 |
| Javle, MM | 1 |
| McCann, SE | 1 |
| Baker, JA | 1 |
| Reid, ME | 1 |
| Natarajan, N | 1 |
| Moysich, KB | 1 |
| Grau, MV | 1 |
| Rees, JR | 1 |
| Watson, RG | 1 |
| Murphy, SJ | 1 |
| Ferguson, HR | 1 |
| Comber, H | 1 |
| McGuigan, J | 1 |
| Reynolds, JV | 1 |
| Odemis, B | 1 |
| Ataseven, H | 1 |
| Basar, O | 1 |
| Ertugrul, I | 1 |
| Yüksel, O | 1 |
| Turhan, N | 1 |
| Konturek, PC | 1 |
| Kania, J | 1 |
| Burnat, G | 1 |
| Hahn, EG | 1 |
| Jiménez, P | 1 |
| García, A | 1 |
| Bolieva, LZ | 1 |
| Dzhioev, FK | 1 |
| Kakabadze, SA | 1 |
| Zhou, QZ | 1 |
| Liu, HB | 1 |
| Ding, XC | 1 |
| You, H | 1 |
| Jia, JD | 1 |
| Morgan, GP | 1 |
| Thun, MJ | 1 |
| Namboodiri, MM | 1 |
| Calle, EE | 1 |
| Flanders, WD | 1 |
| Heath, CW | 1 |
| Concannon, MJ | 1 |
| Meng, L | 1 |
| Welsh, CF | 1 |
| Puckett, CL | 1 |
| Morgan, G | 5 |
| Funkhouser, EM | 1 |
| Sharp, GB | 1 |
| Hill, MJ | 1 |
| Farrow, DC | 1 |
| Hansten, PD | 1 |
| Stanford, JL | 1 |
| Risch, HA | 1 |
| Gammon, MD | 1 |
| Chow, WH | 1 |
| Dubrow, R | 1 |
| Ahsan, H | 1 |
| Mayne, ST | 1 |
| Schoenberg, JB | 1 |
| West, AB | 1 |
| Rotterdam, H | 1 |
| Fraumeni, JF | 1 |
| Blot, WJ | 1 |
| Li, M | 1 |
| Lotan, R | 1 |
| Levin, B | 1 |
| Tahara, E | 1 |
| Lippman, SM | 1 |
| Xu, XC | 1 |
| Vainio, H | 1 |
| Sjödahl, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study To Define The Role Of Various Factors In Development And Progression Of Gastroesophageal Reflux Disease (GERD) And Barrett's Esophagus And The Creation Of A Registry.[NCT00574327] | 3,000 participants (Anticipated) | Observational | 2006-01-31 | Recruiting | |||
| Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project[NCT00586404] | 1,250 participants (Actual) | Observational | 2007-11-30 | Terminated (stopped due to lack of enrollment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for aspirin and Esophageal Neoplasms
| Article | Year |
|---|---|
Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review.
Topics: Analgesics, Opioid; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Esophag | 2023 |
Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review.
Topics: Aspirin; Chemoprevention; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Meta-Ana | 2020 |
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Esophageal Neoplasms; Humans | 2020 |
Current Status of Chemoprevention in Barrett's Esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Chemoprevention; Drug Therapy, Combination; Esophageal N | 2021 |
Lifestyle interventions can reduce the risk of Barrett's esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants.
Topics: Adenocarcinoma; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Aspirin; B | 2021 |
Low-Dose Aspirin Use Does Not Increase Survival in 2 Independent Population-Based Cohorts of Patients With Esophageal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Databases, Factual; Engla | 2018 |
Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis.
Topics: Anticarcinogenic Agents; Aspirin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Public | 2013 |
The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; | 2014 |
Strategies to improve outcomes in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi | 2014 |
Aspirin and esophageal squamous cell carcinoma: bedside to bench.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Es | 2014 |
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Disease Progres | 2016 |
Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; ErbB Recepto | 2008 |
Chemoprevention of oesophageal cancer and the AspECT trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Clinical Trials as Topic; Esome | 2009 |
[Cyclooxygenase inhibitors in chemoprevention and treatment of esophageal squamous cell carcinoma].
Topics: Animals; Aspirin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Esophagea | 2009 |
Chemoprevention in Barrett's esophagus: A pill a day?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Diet; Esophagea | 2011 |
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St | 2011 |
Meta-analysis: non-steroidal anti-inflammatory drug use and the risk of esophageal squamous cell carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Carcinoma, Squamous Cell; | 2011 |
Acid reflux and oesophageal cancer.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas | 2011 |
Aspirin and NSAIDs; benefits and harms for the gut.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cardiovascular Disease | 2012 |
Aspirin and cancer risk: an update to 2001.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Stu | 2002 |
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Dose-Res | 2003 |
[Medical treatment of Barrett's esophagus].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cycloo | 2005 |
Chemoprevention in gastrointestinal cancers: current status.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Clinical Trials as Topi | 2006 |
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cell Transformation, Neop | 2007 |
Aspirin chemoprevention of colorectal and oesophageal cancers. An overview of the literature and homeopathic explanation.
Topics: Aspirin; Colorectal Neoplasms; Esophageal Neoplasms; Homeopathy; Humans; Risk Factors | 1996 |
Non-steroidal anti-inflammatory drugs and chemoprevention of cancer.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Case-Control Studie | 2000 |
Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2001 |
6 trials available for aspirin and Esophageal Neoplasms
| Article | Year |
|---|---|
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Ther | 2019 |
Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Carcinogenesis; Cell Line, Tumor; Cell Prolifer | 2019 |
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemotherapy, Adjuvant; Colorect | 2016 |
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous C | 2009 |
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cohort Studies; Demography; Eso | 2009 |
Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial pathology audit.
Topics: Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Disease Progression; Esomeprazole; Esophageal Neoplas | 2012 |
69 other studies available for aspirin and Esophageal Neoplasms
| Article | Year |
|---|---|
Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Esophageal Neoplas | 2022 |
Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.
Topics: Adenocarcinoma; Aspirin; Case-Control Studies; Chemoprevention; Esophageal Neoplasms; Esophageal Squ | 2022 |
Effect of taking aspirin before diagnosis on the prognosis of esophageal squamous cell carcinoma and analysis of prognostic factors.
Topics: Aspirin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Esophageal Neoplasms; Esophageal Squamous Cell | 2022 |
Aspirin Exerts Its Antitumor Effect in Esophageal Squamous Cell Carcinoma by Downregulating the Expression of ATAD2 and KIF4A.
Topics: Aspirin; ATPases Associated with Diverse Cellular Activities; Cell Line, Tumor; Cell Movement; Cell | 2022 |
Barrett Esophagus: Rapid Evidence Review.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Humans; | 2022 |
Aspirin or statin use in relation to survival after surgery for esophageal cancer: a population-based cohort study.
Topics: Aspirin; Cohort Studies; Esophageal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 2023 |
The regulation of acetylation and stability of HMGA2 via the HBXIP-activated Akt-PCAF pathway in promotion of esophageal squamous cell carcinoma growth.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Animals; Aspirin; Cell Line, Tumor; DNA; Esophage | 2020 |
Low-dose aspirin and risk of gastric and oesophageal cancer: A population-based study in the United Kingdom using The Health Improvement Network.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2020 |
Concurrent β-blocker Use is Associated With Improved Outcome in Esophageal Cancer Patients Who Undergo Chemoradiation: A Retrospective Matched-pair Analysis.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; | 2020 |
Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells.
Topics: Animals; Aspirin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dimethylnitrosamin | 2021 |
Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Esophagus; Humans; Proton Pump Inh | 2018 |
[Aspirin inhibits cell stemness of esophageal cancer by downregulation of chemokine CCL2].
Topics: Antineoplastic Agents; Aspirin; Cell Line, Tumor; Chemokine CCL2; Chemokines; Down-Regulation; Esoph | 2018 |
The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colorect | 2019 |
Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett's Esophagus?
Topics: Aspirin; Barrett Esophagus; Esomeprazole; Esophageal Neoplasms; Humans; Proton Pump Inhibitors | 2019 |
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Aspirin; Barrett Esophagus; Case-Control Studies; Chemoprev | 2014 |
Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model.
Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Dinoprostone; Disease Models, Animal; Esophagea | 2014 |
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St | 2015 |
On Trial: Evidence From Using Aspirin to Prevent Cancer.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Clinical Trials as | 2015 |
Cancers prevented in Australia in 2010 through the consumption of aspirin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Aspirin; Australia; Carcinoma, Squamous Cell; Colore | 2015 |
Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort | 2015 |
The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Esophageal Neoplasms; Fem | 2016 |
Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caspase 3; Cel | 2016 |
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Cont | 2016 |
Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; bcl-2-Associated X Protein; Blotting, W | 2009 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Aspirin; Cell Line, Tumor; Chenodeoxycholic Acid; Cholagogues | 2008 |
Influence of aspirin and cigarette smoke extract on the expression of cyclin D1 and effects of cell cycle in esophageal squamous cell carcinoma cell line.
Topics: Analysis of Variance; Aspirin; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, T | 2009 |
Effects of the inhibition of cyclooxygenase-2 on human esophageal cancer cells: inhibition of cell proliferation and induction of apoptosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blotting, Western; Carcinoma, Squamous | 2010 |
Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2010 |
Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Algorithms; Anticarcinogenic Agents; Aspirin; Calibration; Cost-Benefit Analy | 2010 |
Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy: preliminary study.
Topics: Aged; Aspirin; Cardiovascular Agents; Duodenal Ulcer; Endoscopy, Digestive System; Esophageal Neopla | 2010 |
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cell Growth Processes; | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop | 2011 |
Killing two birds with one salicylate: aspirin's dual roles in preventative health.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anticarcinogenic Agents; Aspirin; Cardiovascular Agents; Car | 2011 |
Esophageal mucosal lesion with low-dose aspirin and prasugrel mimics malignancy: a case report.
Topics: Aspirin; Diagnosis, Differential; Drug-Eluting Stents; Esophageal Neoplasms; Esophagus; Humans; Inte | 2011 |
Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Aspirin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cycloox | 2011 |
Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blotting, Western; Caspase 3; | 2012 |
Aspirin: the balance between benefits and harms. Preface.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Common | 2012 |
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett E | 2012 |
Aspirin use and cancers of the upper aerodigestive tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Case-Control Studies; Es | 2003 |
NSAIDS and esophageal cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Esophage | 2003 |
Aspirin for cancer chemoprevention: still a headache?
Topics: Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Cyclooxygenase Inhibitor | 2004 |
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Topics: Aged; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Drug Costs; Esopha | 2004 |
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Topics: Adenocarcinoma; Adult; Aged; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; D | 2004 |
Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Acids and Sal | 2005 |
Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control | 2004 |
Optimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Eso | 2005 |
Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2.
Topics: Apoptosis; Aspirin; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Nucleus; Cycloox | 2005 |
Regular aspirin use and esophageal cancer risk.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Car | 2006 |
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Topics: Acetaminophen; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2006 |
Ulcer in the basis of Zenker's diverticulum mimicking esophageal malignancy.
Topics: Aged; Alcohol Drinking; Aspirin; Diagnosis, Differential; Diverticulitis; Endoscopy; Esophageal Neop | 2006 |
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Barrett Esophagus; Casp | 2006 |
Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biomarkers, Tum | 2007 |
Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Celecoxib; Dieth | 2007 |
Aspirin inhibits the proliferation of tobacco-related esophageal squamous carcinomas cell lines through cyclooxygenase 2 pathway.
Topics: Aspirin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxyg | 2007 |
COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID.
Topics: Aspirin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxyg | 2008 |
Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus.
Topics: Acetaminophen; Adenocarcinoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2008 |
NSAIDs and the chemoprevention of colon and oesophageal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Esophageal Neoplasms; Humans; P | 1995 |
Aspirin use and risk of fatal cancer.
Topics: Acetaminophen; Aspirin; Colonic Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Female; | 1993 |
Inhibition of perioperative platelet aggregation using toradol (ketorolac).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Contraindications; Drug | 1993 |
Relationship between colorectal and esophageal cancer.
Topics: Aspirin; Barrett Esophagus; Colorectal Neoplasms; Esophageal Neoplasms; Humans | 1996 |
Aspirin and reduced risk of esophageal carcinoma.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Esophageal Neoplasms; | 1995 |
Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Esophageal Neoplasms; Humans | 1996 |
Aspirin, NSAIDS and human cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Esophageal Neoplasms; Humans | 1996 |
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; | 1998 |
Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cell Transforma | 1998 |
Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blotting, Western; Cyclooxygena | 2000 |